epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-620, Phase III. In planning

Chronic obstructive pulmonary disease with frequent exacerbations

LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.

Every risk that applies to this study, scored after TransCelerate's risk assessment tool. The KRIs and QTLs tabs set out what watches each one.

This study carries 27 risks

They come from its protocol answers, its countries and the kinds of site it uses: four score high and nine medium. Of those, nine are not yet watched by any KRI, KPI or QTL. A new KRI or a closer look there would lower the risk most.

ScoreRiskWhy it applies hereL×I×DWatched by
18HighPlacebo or no-added-treatment control armPD-05, evidence grade B; design riskWhat does the control arm receive? Placebo or no added treatment3×3×2QTL: stopped study treatment early
18HighActive comparator (against placebo) in registry dataPD-17, evidence grade B; design riskWhat does the control arm receive? Placebo or no added treatment3×2×3Nothing yet
18HighFragmented, negotiated costing and contractingPOL-03, evidence grade A; country riskUnited Kingdom: Costing and contracting were the longest start-up step; the national contract has shortened it · Spain: Site contracts took 117 days in 2016 and about 90 after national templates3×2×3Nothing yet
18HighEthics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness)POL-20, evidence grade B; country riskPoland: A central ethics committee reviews every study; its effect on timelines is not measured3×2×3Nothing yet
12MediumComorbidity exclusionsPD-15, evidence grade B; design riskDoes the protocol exclude common comorbidities? Yes2×3×2QTL: ineligible patients randomised
12MediumBlinded placebo-controlled design instead of open-labelEB-03, evidence grade A; design riskIs the study blinded? Blinded2×2×3Nothing yet
12MediumBlinded placebo-controlled against open designPD-06, evidence grade A; design riskIs the study blinded? Blinded2×2×3Nothing yet
12MediumWashout periods and concomitant-medication exclusionsPD-09, evidence grade C; design riskIs there a run-in or a washout longer than four weeks? Yes2×2×3Nothing yet
12MediumRun-in period before randomisationPD-10, evidence grade C; design riskIs there a run-in or a washout longer than four weeks? Yes2×2×3Nothing yet
12MediumBiomarker-selected population with low marker prevalencePD-12, evidence grade B; design riskDoes entry require a biomarker, and how common is it? Yes, in more than half of patients2×2×3Nothing yet
12MediumDecentralised elementsPD-20, evidence grade C; design riskAre any visits done remotely or at home? Some visits2×2×3Nothing yet
9MediumMandatory audio-visual consent for all participantsRW-03, evidence grade C; country riskIndia: Vulnerable participants in trials of new drugs need an audio-visual record of their consent3×3×1KRI: consent findings
9MediumCurrency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026)RW-07, evidence grade D; country riskTurkey: A fixed pharmaceutical exchange rate has caused repeated medicine shortages3×3×1KRI: study drug at the site; QTL: stopped study treatment early
6LowRestrictive eligibility criteria and protocol complexityEB-04, evidence grade B; design riskHow many non-essential exclusions does the protocol carry? One or two2×3×1KRI: screen failure above the study's; QTL: ineligible patients randomised
6LowEligibility criteria exclude patients (comorbidity, age, performance status, language)PB-02, evidence grade A; design riskHow many non-essential exclusions does the protocol carry? One or two · Does the protocol exclude common comorbidities? Yes2×3×1KRI: screen failure above the study's; QTL: ineligible patients randomised
6LowRestrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status)PD-01, evidence grade A; design riskHow many non-essential exclusions does the protocol carry? One or two2×3×1KRI: screen failure above the study's; QTL: ineligible patients randomised
6LowNumber of eligibility criteria and complexity growthPD-02, evidence grade B; design riskHow many non-essential exclusions does the protocol carry? One or two2×3×1KRI: screen failure above the study's; KRI: important protocol deviations; QTL: ineligible patients randomised
6LowRacial and ethnic under-representationPB-12, evidence grade A; country riskUnited States: Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies3×2×1KRI: enrolment against the diversity plan
6LowThe US activates its first site quickly but scales its site fleet slowlyPM-03, evidence grade B; country riskUnited States: The first US site opens quickly, but the rest of the US sites open slowly3×2×1KRI: site activation overdue
6LowStart-up time for India and Turkey is unmeasuredPM-04, evidence grade C; country riskTurkey: Start-up time has not been measured since CRO data from 2014 and 2015 · India: Start-up time is unmeasured beyond the statutory 90 working days3×2×1KRI: site activation overdue
6LowRegulator assessment backlogPOL-02, evidence grade A; country riskUnited Kingdom: The regulator's backlog of 2023 was cleared, but could recur1×2×3Nothing yet
6LowRegional regulatory transition friction (EU CTR and CTIS)POL-15, evidence grade A; country riskSpain: Applications go through the EU Clinical Trials Regulation and its portal · Poland: Applications go through the EU Clinical Trials Regulation and its portal3×2×1KRI: site activation overdue
6LowEthics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024)RW-05, evidence grade B; country riskTurkey: Ethics committees fell from 145 to 49 in 2024, cutting review capacity3×2×1KRI: site activation overdue
6LowPast performance as a predictorS-04, evidence grade B; design riskHave most sites worked with the sponsor before? Yes, mostly repeat sites1×2×3Nothing yet
6LowCompeting trialsS-21, evidence grade B; design riskHow many competing trials recruit the same patients? A few1×2×3Nothing yet
6LowMajor earthquake in a site regionSH-11, evidence grade C; country riskTurkey: Sites in the south-east lie in the 2023 earthquake zone1×2×3Nothing yet
2LowSite type: activation speedS-06, evidence grade A; design riskWhat kind of sites will the study mostly use? A mix1×2×1KRI: site activation overdue; Study KPIs

How the scores are worked out

  • Likelihood. From the answer that switched the risk on: 3 if it cuts the recruitment rate to ×0.75 or below, 2 if it cuts it at all or changes screening or retention, 1 otherwise. From the risk's scope in the country: 3 if it touches all of the country's sites, 2 if some, 1 if only should an event recur. From the share of the study's sites whose profile carries the risk: 3 at 40% or more, 2 at 15% or more, 1 below.
  • Impact. Scores 3 if the risk threatens the result, the patients' safety or their rights; 1 if it mainly adds cost; 2 for everything else, which mostly delays recruitment.
  • Detectability. Scores 1 if a site-level KRI watches the risk every month, 2 if only a study-level KPI or QTL does, 3 if nothing does. A watched risk scores lower, so adding a KRI lowers the score.
  • Bands. High from 18, medium from 8, out of 27.
  • Method after TransCelerate RACT (2013); rules and cut-offs are epiClinical assumptions.